Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=18711404&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
The use of high-sensitivity assays for C-reactive protein in clinical practice Musunuru K; Kral BG; Blumenthal RS; Fuster V; Campbell CY; Gluckman TJ; Lange RA; Topol EJ; Willerson JT; Desai MY; Davidson MH; Mora SNat Clin Pract Cardiovasc Med 2008[Oct]; 5 (10): 621-35High-sensitivity assays that accurately measure levels of the inflammatory biomarker C-reactive protein have been proposed for use in assessments of risk for cardiovascular disease (CVD). A growing body of evidence supports recommendations for these tests in selected asymptomatic individuals deemed to be at intermediate risk of CVD according to traditional risk-factor assessments and who do not already warrant chronic treatment with aspirin and statin therapy. Data suggests that these high-sensitivity assays should be used in combination with measurements of LDL-cholesterol levels to assist risk stratification of selected patients for prevention of CVD.|Aged[MESH]|Biomarkers/blood[MESH]|C-Reactive Protein/*analysis[MESH]|Cardiovascular Diseases/blood/*etiology/prevention & control[MESH]|Cholesterol, LDL/blood[MESH]|Cost-Benefit Analysis[MESH]|Diabetes Complications/blood/etiology[MESH]|Female[MESH]|Humans[MESH]|Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use[MESH]|Hypertension/blood/complications[MESH]|Inflammation Mediators/*blood[MESH]|Male[MESH]|Metabolic Syndrome/blood/complications[MESH]|Middle Aged[MESH]|Predictive Value of Tests[MESH]|Risk Assessment[MESH]|Risk Factors[MESH]|Risk Reduction Behavior[MESH]|Secondary Prevention[MESH]|Sensitivity and Specificity[MESH] |
